CD4 News and Research

RSS

Granzyme K+ CD8+ T-cells identified as key drivers of recurrent airway inflammation

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent respiratory diseases.

17 Jan 2025

Immune system changes may predict antipsychotic resistance in schizophrenia Scientis...

Researchers from the National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, Technology and Research (A*STAR) have made strides in understanding the connection between the immune system and resistance to antipsychotic medications in schizophrenia, using changes in immune cell populations to predict potential treatment resistance and initiate the most appropriate treatment sooner.

16 Jan 2025

Single-dose malaria vaccine offers unprecedented 90% protection

Results from the malaria vaccine trial indicate that GA2 immunization provides significant protection, paving the way for more effective vaccination strategies.

8 Jan 2025

Topical immunotherapy clears precancerous skin lesions and reduces cancer risk

Calcipotriol-plus–5-FU therapy activates immune pathways, offering long-lasting protection against squamous cell carcinoma by targeting precancerous lesions.

6 Jan 2025

Study identifies novel IgAN loci through pleiotropy

IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis characterized by the deposition of IgA in the glomerular mesangium, leading to a spectrum of histopathological lesions and a variable clinical course that can progress to end-stage renal disease in a significant proportion of patients.

2 Jan 2025

New immunotherapy shows long-term benefits in preventing squamous cell carcinoma

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment.

2 Jan 2025

A scaffolded vaccine approach for broader influenza protection

Most people who get the seasonal influenza vaccine – which contains strains of viruses from distinct virus subtypes – mount a strong immune response to one strain, leaving them vulnerable to infection by the others, and researchers have long wondered what impacts such variable responses more – host genetics or prior exposure to virus strains.

19 Dec 2024

Breakthrough discovery could lead to effective vaccine for S. aureus

Staphylococcus aureus (S. aureus) is a major cause of skin and soft tissue infections that can sometimes lead to sepsis and toxic shock syndrome.

16 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

Engineered immune cells could transform treatment for autoimmune diseases

Immune cells that are designed to soothe could improve treatment for organ transplants, type 1 diabetes and other autoimmune conditions.

9 Dec 2024

Late-liver-stage malaria vaccine delivers 89% protection and boosts cellular immunity

Genetically attenuated malaria parasites with extended liver-stage arrest (GA2) showed 89% protection in a clinical trial, surpassing earlier vaccine candidates and highlighting the potential of cellular immunity.

26 Nov 2024

WHO grants Emergency Use Listing for LC16m8 mpox vaccine

The World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by WHO following the Director-General's declaration of an mpox public health emergency of international concern (PHEIC) on 14 August 2024.

19 Nov 2024

Study uncovers key mechanism behind HIV latency

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.

18 Nov 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

MEMPHIS system sheds light on vaccine response differences across ages

mRNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than did younger adults. Why? Boston Children's researchers, led by Byron Brook, PhD, and Ofer Levy, MD, PhD, have found some answers, while providing proof-of-concept of a new system that can model vaccine responses in a dish.

15 Nov 2024

New biomarker could predict response to IBD treatment

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

7 Nov 2024

How a ketogenic diet could reduce autoimmune disease severity through host-microbiome interactions

This study uncovers the ketogenic diet's effects on the microbiome, revealing its potential to mitigate autoimmune diseases through metabolic pathways.

6 Nov 2024

Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis

Researchers identified a unique antibody signature against the Epstein-Barr virus protein EBNA1 that correlates with cross-reactive immune responses in multiple sclerosis (MS) patients. This connection provides new insights into how EBV infection may drive MS pathogenesis.

5 Nov 2024

Research uncovers intrinsic factors influencing CAR-T cell success

Researchers from the Josep Carreras Leukaemia Research Institute have found that the efficacy of varni-cel, a CAR-T infusion product for B-ALL patients, is highly dependent on intrinsic features of the CAR-T cells themselves and their progression within the patient.

29 Oct 2024